Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment. 2023

Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
Department of Oncology, National Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway.

Chronic fatigue (CF), substantial fatigue for ≥ six months, can manifest as a late effect (LE) after cancer treatment, and may affect several aspects of life. In a Norwegian cohort of Hodgkin's lymphoma survivors (HLS), more than a decade after contemporary risk-adapted treatment regimens with limited use of radiotherapy (RT), we assessed: (1) Prevalence of, (2) factors associated with (3) and implications of CF on socioeconomic status (SES) and work ability (WA). HLS treated between 1997-2006, aged 8-49 years at diagnosis, were invited to participate in a population-based cross-sectional study on late effects in 2018-2019. In a mailed questionnaire, HLS responded to a fatigue questionnaire (FQ), work ability score (WAS) and short-form health survey (SF-36). Disease- and treatment data were extracted from hospital records. Factors associated with CF were identified by uni- and multivariate analysis. To study the implications of CF on SES and WA, a multinomial regression analysis was performed. Invitations were extended to 518 HLS and 298 (58%) responded to FQ, of whom 42% had CF with mean (standard deviation [SD]) physical- and mental fatigue scores of 10.2 (4.3) and 5.5 (2.1) respectively. Median age at survey was 45 years, 47% were females. In multivariate analysis female sex (p = 0.03), lower education (p = 0.03), body mass index ≥30 kg/m2 (p = 0.04), and an increasing number of comorbidities (p = 0.01) were associated with CF. No association with disease stage, chemotherapy or RT was found. CF was associated with poorer WAS scores at survey (p < 0.001), unemployment (p = 0.03), and receiving disability pension (p = 0.003). After risk-adapted treatment, CF is still a frequent LE among long-term HLS, without apparent association with disease or treatment-related parameters. CF is associated with reduced WA and SES. As no apparent risk reduction is seen with contemporary treatment, further studies should emphasize etiological factors of CF and treatment to alleviate this common LE.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015673 Fatigue Syndrome, Chronic A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9) Chronic Fatigue Syndrome,Encephalomyelitis, Myalgic,Infectious Mononucleosis-Like Syndrome, Chronic,Postviral Fatigue Syndrome,Chronic Fatigue Disorder,Chronic Fatigue and Immune Dysfunction Syndrome,Chronic Fatigue-Fibromyalgia Syndrome,Myalgic Encephalomyelitis,Royal Free Disease,Systemic Exertion Intolerance Disease,Chronic Fatigue Disorders,Chronic Fatigue Fibromyalgia Syndrome,Chronic Fatigue Syndromes,Chronic Fatigue-Fibromyalgia Syndromes,Fatigue Disorder, Chronic,Fatigue Syndrome, Postviral,Fatigue Syndromes, Chronic,Fatigue-Fibromyalgia Syndrome, Chronic,Fatigue-Fibromyalgia Syndromes, Chronic,Infectious Mononucleosis Like Syndrome, Chronic,Postviral Fatigue Syndromes,Syndrome, Postviral Fatigue
D017741 Survivors Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events. Long-Term Survivors,Long Term Survivors,Long-Term Survivor,Survivor,Survivor, Long-Term,Survivors, Long-Term

Related Publications

Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
January 2012, Tumori,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
February 2006, European journal of cancer (Oxford, England : 1990),
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
June 2008, International journal of radiation oncology, biology, physics,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
November 2010, Psycho-oncology,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
April 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
October 2003, European journal of cancer (Oxford, England : 1990),
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
January 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
January 2021, Upsala journal of medical sciences,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
September 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Siri A Eikeland, and Knut B Smeland, and Victoria Charlotte Simensen, and Unn-Merete Fagerli, and Hanne S Bersvendsen, and Cecilie E Kiserud, and Alexander Fosså
February 2022, Leukemia & lymphoma,
Copied contents to your clipboard!